Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35093912/
1 Department of Breast Surgery, Saitama Medical Center, Saitama, Japan; [email protected]. 2 Department of Breast Surgery, Saitama Medical Center, Saitama, Japan. 3 Department of Pathology, Saitama Medical Center, Saitama, Japan....
Conclusion: BOR to prior-palbociclib was the only independent predictive factor for PFS in ER /HER2- MBC patients undergoing subsequent-abemaciclib after disease progression on prior-palbociclib.
Determinants of Response to Talazoparib in Patients with HER2-negative, Germline BRCA1/2-mutated Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35091441/
Overall, BRCA LOH status, DDR gene mutational burden, and gLOH were not associated with talazoparib efficacy; however, these conclusions are qualified by population heterogeneity and low patient numbers in some...
Conclusions: Overall, BRCA LOH status, DDR gene mutational burden, and gLOH were not associated with talazoparib efficacy; however, these conclusions are qualified by population heterogeneity and low patient numbers in some subgroups. Further investigation in larger patient populations is warranted.
Examining the prevalence of homologous recombination repair defects in ER+ breast cancers - Breast Cancer Research and Treatment
Source : https://link.springer.com/article/10.1007/s10549-022-06529-z
Purpose Homologous recombination deficiency (HRD) is well characterized in triple-negative breast cancer (TNBC), but its prevalence in the hormone-receptor-positive breast cancer subtypes is not as clearly defined. It is estimated...
Conclusion: Our analyses suggest that 14% of ER /Her2− patients may be HRD and therefore potentially eligible for treatments with HRD-directed therapies such as platinum agents and PARP inhibitors. As the ER /Her2− subtype is the most common breast cancer subtype, this group of HRD patients is likely more sizable than that of HRD TNBC...
Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35008374/
Breast cancer remains a leading cancer burden among women worldwide. Acquired resistance of cyclin-dependent kinase (CDK) 4/6 inhibitors occurs in almost all hormone receptor (HR)-positive subtype cases, comprising 70% of...
Conclusion/Relevance: The sequential combination of abemaciclib following eribulin merits further clinical trials to overcome resistance to CDK4/6 inhibitors in HR-positive breast cancer.
Oral Abundance of Actinomyces spp. in Breast Cancer Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35051923/
We suggest that Actinomyces spp. are not the initiative factor in MRONJ development. These bacteria are not altered in abundance during chemotherapy, but they behave opportunistic when there is a...
Conclusions: We suggest that Actinomyces spp. are not the initiative factor in MRONJ development. These bacteria are not altered in abundance during chemotherapy, but they behave opportunistic when there is a bone disruption in the oropharynx in the first place caused by antiresorptive drugs or dental trauma and proliferate in their new niche....